{"id":"W4387809682","doi":"10.1016/j.annonc.2023.10.011","title":"LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":134,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme; Seagen; Genentech; Hope Foundation; AstraZeneca; Breast Cancer Research Foundation; Pfizer; Bristol-Myers Squibb; Merck","keywords":"Medicine; Pembrolizumab; Oncology; Stage (stratigraphy); Adjuvant; Chemotherapy; Breast cancer; Adjuvant chemotherapy; Internal medicine; Gynecology; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001319144,0.00181437,0.001812494,0.0005115011,0.0005301585,0.001346214,0.001314577,0.001474816,0.007256688],"category_scores_gemma":[0.0007223399,0.000666259,0.001473768,0.0003993732,0.0009996693,0.0008201001,0.0003605038,0.004339616,0.002110854],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001130965,"about_ca_system_score_gemma":0.00223197,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002319679,"about_ca_topic_score_gemma":0.006996404,"domain_scores_codex":[0.9997113,0.0001154569,0.00001143231,0.00004689065,0.00002298219,0.00009188365],"domain_scores_gemma":[0.9995688,0.00005911582,0.00005808055,0.00003114232,0.0000180333,0.0002649259],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7878141,0.06674572,0.001671311,0.001171588,0.00150188,0.0001403465,0.0001788755,0.002246268,0.03900313,0.0006798208,0.008736713,0.09011019],"study_design_scores_gemma":[0.7297418,0.2569591,0.004097544,0.00005542313,0.0006368796,0.0001327267,0.00005391338,0.0008580588,0.003061409,0.0002465053,0.004120706,0.00003592954],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9763084,0.00523868,0.0008103252,0.00141609,0.0007800115,0.003699197,0.003311448,0.0003859349,0.008049897],"genre_scores_gemma":[0.9639707,0.005274617,0.00299988,0.002258515,0.0004592662,0.004767783,0.005995344,0.00009012914,0.01418363],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007256688,"threshold_uncertainty_score":0.02427602,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1272431833263286,"score_gpt":0.4865900282985598,"score_spread":0.3593468449722312,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}